Pyrazolopyridine Compounds Broad-Spectrum Antiviral Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments lack effective inhibitors for enteroviruses, paramyxoviruses, respiratory viruses, flaviviridae viruses, bunyaviridae viruses, and togaviridae viruses, particularly in preventing replication and cell death caused by these pathogens.
Innovation Solution
Development of compounds represented by Formulas I, II, and III, which include specific chemical structures that inhibit viral replication and cell death by contacting infected cells with effective amounts of these compounds, thereby treating viral infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for viral infections, then existing therapeutic options are available, but effective inhibitors for enteroviruses, paramyxoviruses, respiratory viruses, flaviviridae viruses, bunyaviridae viruses, and togaviridae viruses are lacking
Solution Approach 1:
The pyrazolopyridine compounds of Formula I are designed to function as broad-spectrum antiviral agents effective against multiple virus families including enteroviruses, paramyxoviruses, respiratory viruses, flaviviridae viruses, bunyaviridae viruses, and togaviridae viruses. The core molecular structure with variable R groups enables a single compound class to target diverse viral replication mechanisms across different virus families, providing universal antiviral protection.
Solution Approach 2:
The patent employs systematic variation of chemical parameters (R1-R6 substituents on the pyrazolopyridine core) to optimize antiviral potency and spectrum. By changing molecular parameters such as aromatic substituents, heterocyclic groups, and functional moieties at different positions, the compounds achieve enhanced reliability across multiple virus types while maintaining selective toxicity.
2Productivity
If compounds of Formula I are used to inhibit viral replication, then replication is inhibited and cell death is reduced, but specific chemical structure requirements must be met
Solution Approach 1:
The antiviral compound is segmented into a core pyrazolopyridine structure (providing essential antiviral activity) and variable substituent groups (R1-R6) that can be independently optimized. This segmentation allows the core structure to maintain replication inhibition efficacy while peripheral groups are tailored for specific virus targets, reducing the complexity burden on the essential functional core.
Solution Approach 2:
Different regions of the molecule have specialized functions: the pyrazolopyridine core provides the essential antiviral mechanism, while specific substituents (R2-R6) provide virus-specific binding affinity and selectivity. This local quality differentiation enables the compound to achieve high productivity against viral replication without requiring the entire molecule to be overly complex, as each region contributes specifically to its function.
Data Source
AI summary
The present technology provides compounds according to Formulas (I), (II), or (III) useful in inhibiting an enterovirus, paramyxovirus, respiratory virus, flaviviridae virus, bunyaviridae virus, togaviridae virus, or rabies virus in a cell and/or treating subjects suffering from an enterovirus, paramyxovirus, respiratory virus, flaviviridae virus, bunyaviridae virus, togaviridae virus, or rabies virus.